# InfuSystem Holdings, Inc: overview INFU · NYSE · CIK 1337013 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/infu.md) · [Financials](/companies/infu/financials.md) · [Filings](/companies/infu/filings.md) · [Insiders](/companies/infu/insiders.md) Latest reported revenue: [$36.9m](/filings/0001628280-26-052462.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 4, 2026 (XBRL us-gaap:Revenues, accession 0001628280-26-052462). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [35.3](/filings/0001628280-25-048869.md) | [33.8 d](/filings/0001628280-26-012804.md) | [34.7](/filings/0001628280-26-032737.md) | [36.0](/filings/0001628280-26-052462.md) | [36.5](/filings/0001628280-25-048869.md) | [36.2 d](/filings/0001628280-26-012804.md) | [33.7](/filings/0001628280-26-032737.md) | [36.9](/filings/0001628280-26-052462.md) | | Gross margin | % | [53.9%](/filings/0001628280-25-048869.md) | [53.8% d](/filings/0001628280-26-012804.md) | [55.2%](/filings/0001628280-26-032737.md) | [55.2%](/filings/0001628280-26-052462.md) | [57.1%](/filings/0001628280-25-048869.md) | [56.4% d](/filings/0001628280-26-012804.md) | [58.4%](/filings/0001628280-26-032737.md) | [58.0%](/filings/0001628280-26-052462.md) | | Operating margin | % | [9.2%](/filings/0001628280-25-048869.md) | [7.7% d](/filings/0001628280-26-012804.md) | [1.8%](/filings/0001628280-26-032737.md) | [10.5%](/filings/0001628280-26-052462.md) | [10.4%](/filings/0001628280-25-048869.md) | [10.3% d](/filings/0001628280-26-012804.md) | [4.7%](/filings/0001628280-26-032737.md) | [11.2%](/filings/0001628280-26-052462.md) | | Net margin | % | [5.1%](/filings/0001628280-25-048869.md) | [2.8% d](/filings/0001628280-26-012804.md) | [(0.8%)](/filings/0001628280-26-032737.md) | [7.2%](/filings/0001628280-26-052462.md) | [6.2%](/filings/0001628280-25-048869.md) | [5.6% d](/filings/0001628280-26-012804.md) | [3.0%](/filings/0001628280-26-032737.md) | [8.7%](/filings/0001628280-26-052462.md) | | Diluted EPS | $ per share | [0.08](/filings/0001628280-25-048869.md) | not reported | [(0.01)](/filings/0001628280-26-032737.md) | [0.12](/filings/0001628280-26-052462.md) | [0.11](/filings/0001628280-25-048869.md) | not reported | [0.05](/filings/0001628280-26-032737.md) | [0.15](/filings/0001628280-26-052462.md) | | Free cash flow | $m | [9.8 d](/filings/0001628280-25-048869.md) | [7.4 d](/filings/0001628280-26-012804.md) | [1.6](/filings/0001628280-26-032737.md) | [6.8 d](/filings/0001628280-26-052462.md) | [8.4 d](/filings/0001628280-25-048869.md) | [7.0 d](/filings/0001628280-26-012804.md) | [0.8](/filings/0001628280-26-032737.md) | [6.7 d](/filings/0001628280-26-052462.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [102](/filings/0001628280-24-015511.md) | [110](/filings/0001628280-24-015511.md) | [126](/filings/0001628280-25-012095.md) | [135](/filings/0001628280-26-012804.md) | [143](/filings/0001628280-26-012804.md) | | Gross margin | % | [57.2%](/filings/0001628280-24-015511.md) | [55.1%](/filings/0001628280-24-015511.md) | [50.2%](/filings/0001628280-25-012095.md) | [52.2%](/filings/0001628280-26-012804.md) | [56.0%](/filings/0001628280-26-012804.md) | | Operating margin | % | [2.8%](/filings/0001628280-24-015511.md) | [1.5%](/filings/0001628280-24-015511.md) | [3.2%](/filings/0001628280-25-012095.md) | [5.1%](/filings/0001628280-26-012804.md) | [8.3%](/filings/0001628280-26-012804.md) | | Net margin | % | [1.4%](/filings/0001628280-24-015511.md) | [0.0%](/filings/0001628280-24-015511.md) | [0.7%](/filings/0001628280-25-012095.md) | [1.7%](/filings/0001628280-26-012804.md) | [4.6%](/filings/0001628280-26-012804.md) | | Diluted EPS | $ per share | [0.06](/filings/0001628280-24-015511.md) | [0.00](/filings/0001628280-24-015511.md) | [0.04](/filings/0001628280-25-012095.md) | [0.11](/filings/0001628280-26-012804.md) | [0.31](/filings/0001628280-26-012804.md) | | Free cash flow | $m | [17.3](/filings/0001628280-24-015511.md) | [16.5](/filings/0001628280-24-015511.md) | [10.2](/filings/0001628280-25-012095.md) | [19.4](/filings/0001628280-26-012804.md) | [23.8](/filings/0001628280-26-012804.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/infu/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $15.3m | 1,585,415 | | Added +968,829 | | [Minerva Advisors LLC](/funds/1541536.md) | 2026-06-30 | $13.0m | 1,348,617 | | Added +144,512 | | [PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.](/funds/1238990.md) | 2026-06-30 | $8.1m | 834,750 | | Reduced −3,175 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $7.6m | 790,775 | | Reduced −69,488 | | [HEARTLAND ADVISORS INC](/funds/937394.md) | 2026-06-30 | $6.8m | 700,000 | | Added +190,000 | | [AMERICAN CENTURY COMPANIES INC](/funds/748054.md) | 2026-06-30 | $6.5m | 675,028 | | Added +202,007 | | [First Eagle Investment Management, LLC](/funds/1325447.md) | 2026-06-30 | $6.0m | 620,000 | | Reduced −101,371 | | [First Eagle Investment Management, LLC](/funds/1325447.md) | 2026-06-30 | $6.0m | 620,000 | | Reduced −101,371 | | [DIMENSIONAL FUND ADVISORS LP](/funds/354204.md) | 2026-06-30 | $5.8m | 599,289 | | Added +5,001 | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $5.2m | 543,009 | | Reduced −23,800 | ## Recent filings [All 1,048 filings](/companies/infu/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-27 | 06:30 ET | [8-K](/filings/0001628280-26-067390.md) | 7.01 Regulation FD disclosure | 0001628280-26-067390 | | 2026-09-17 | 16:30 ET | [8-K](/filings/0001628280-26-062520.md) | 7.01 Regulation FD disclosure | 0001628280-26-062520 | | 2026-08-04 | 15:33 ET | [10-Q](/filings/0001628280-26-052462.md) | Quarterly report, period 2026-06-30 | 0001628280-26-052462 | | 2026-08-04 | 06:46 ET | [8-K](/filings/0001628280-26-052123.md) | 7.01 Regulation FD disclosure | 0001628280-26-052123 | | 2026-08-04 | 06:31 ET | [8-K](/filings/0001628280-26-052112.md) | 2.02 Results of operations | 0001628280-26-052112 | | 2026-07-28 | 07:40 ET | [8-K](/filings/0001628280-26-049931.md) | 7.01 Regulation FD disclosure | 0001628280-26-049931 | | 2026-05-18 | 16:30 ET | [8-K](/filings/0001628280-26-035967.md) | 7.01 Regulation FD disclosure | 0001628280-26-035967 | | 2026-05-14 | 09:04 ET | [8-K](/filings/0001628280-26-034839.md) | 5.02 Departure or appointment of officers or directors | 0001628280-26-034839 | | 2026-05-12 | 17:21 ET | [8-K](/filings/0001628280-26-034217.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results | 0001628280-26-034217 | | 2026-05-08 | 14:06 ET | [10-Q](/filings/0001628280-26-032737.md) | Quarterly report, period 2026-03-31 | 0001628280-26-032737 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-012804.md), filed Feb 27, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/bdaaf95f-975e-4db1-ba7f-f9ee16529e87) ## About the filer - CIK: 1337013 - Tickers: INFU - Exchange: NYSE - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: DE - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 06:32 ET. No prices; not investment advice.